![ECOG-ACRIN logo[19516]275×75](https://blog-ecog-acrin.org/wp-content/uploads/2021/03/ECOG-ACRIN-logo19516275x75.png)
October 19, 2023
Following the recent Nature Medicine publication of lessons from the NCI-MATCH trial, two new podcasts discuss the pitfalls and promises of precision oncology—and opportunities to guide the field as it moves forward
October 19, 2023
Matthias Weiss, MD, of ThedaCare, and Kim Reiss, MD, of the University of Pennsylvania, discuss current trends in precision oncology
August 25, 2023
The changes broaden eligibility for prostate cancer patients and make baseline scanning easier for sites in this phase 3 trial using PET imaging to guide treatment for recurrence
June 30, 2023
Reflections on the spring conference season, including highlights from the recent Group Meeting; updates on the ComboMATCH precision medicine initiative
June 30, 2023
This phase 2 trial is evaluating the activity of nilotinib-paclitaxel in patients with solid tumors and exploring predictive biomarkers of response and resistance
June 30, 2023
At a recent meeting, ECOG-ACRIN leaders and members celebrated the conclusion of enrollment to the landmark NCI-MATCH clinical trial
April 19, 2023
The ComboMATCH registration trial opens; NCI creates Clinical Trials Innovation unit, unveils revised National Cancer Plan
April 19, 2023
ComboMATCH researchers are discovering new drug combinations that show promise for patients with advanced cancers, based on strong pre-clinical in vivo evidence of therapeutic effectiveness
April 19, 2023
Summaries of recently published ECOG-ACRIN research results
February 10, 2023
Summaries and links to timely information about research results in medical journals, recognition of research leaders, and more
December 20, 2022
Reflections on NCI-MATCH and its successor trials; research results in leukemia and breast cancer; and grant renewal preparations
December 20, 2022
This phase 2 study is examining whether the addition of cisplatin to PORT will provide a survival benefit to certain patients with stage 3/4 squamous cell carcinoma of the head and neck